TITLE

DNA Priming-Protein Boosting Enhances Both Antigen-Specific Antibody and Th1-Type Cellular Immune Responses in a Murine Herpes Simplex Virus-2 gD Vaccine Model

AUTHOR(S)
Sin, Jeong-Im; Bagarazzi, Mark; Pachuk, Catherine; Weiner, David B.
PUB. DATE
October 1999
SOURCE
DNA & Cell Biology;Oct99, Vol. 18 Issue 10, p771
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
It has previously been reported that herpes simplex virus (HSV)-2 gD DNA vaccine preferentially induces Thelper (Th) 1-type cellular immune responses, whereas the literature supports the view that subunit vaccines tend to induce potent antibody responses, supporting a Th2 bias. Here, using an HSV gD vaccine model, we investigated whether priming and boosting with a DNA or protein vaccine could induce both potent antibody and Th1-type cellular immune responses. When animals were primed with DNA and boosted with protein, both antibody and Th-cell proliferative responses were significantly enhanced. Furthermore, production of Th1-type cytokines (interleukin-2, interferion-gamma) was enhanced by DNA priming-protein boosting. In contrast, protein priming-DNA boosting produced antibody levels similar to those following protein-protein vaccination but failed to further enhance Th-cell proliferative responses or cytokine production. DNA priming-protein boosting resulted in an increased IgG2a isotype (a Th1 indicator) profile, similar to that induced by DNA-DNA vaccination, whereas protein priming-DNA boosting caused an increased IgG1 isotype (a Th2 indicator) profile similar to that seen after protein-protein vaccination. This result indicates that preferential induction of IgG1 or IgG2a isotype is determined by the type of priming vaccine used. Thus, this study suggests that HSV DNA priming-protein boosting could elicit both potent Th1-type cellular immune responses and antibody responses, both of which likely are important for protection against HSV infection.
ACCESSION #
6463053

 

Related Articles

  • 634. Engineered Herpes Simplex Virus Expressing IL-12 for the Treatment of Experimental Brain Tumors. Miyamoto, Shinya; Ino, Yasushi; Fukuhara, Hiroshi; Todo, Tomoki // Molecular Therapy;Jun2006, Vol. 13, pS244 

    Oncolytic herpes simplex virus type 1 (HSV-1) vectors are promising therapeutic agents for cancer. Their efficacy depends on the extent of both intratumoral viral replication and induction of a host antitumor immune response. Genetically engineered HSV-1 expressing various cytokines can improve...

  • Cancer Gene Therapy through Autonomous Parvovirus - Mediated Gene Transfer. Cornelis, Jan J.; Lang, Susanne I.; Stroh-Dege, Alexandra Y.; Balboni, Ginette; Dinsart, Christiane; Rommelaere, Jean // Current Gene Therapy;Sep2004, Vol. 4 Issue 3, p249 

    Parvoviruses are small nuclear replicating DNA viruses. The rodent parvoviruses are usually weakly pathogenic in adult animals, bind to cell surface receptors which are fairly ubiquitously expressed on cells, and do not appear to integrate into host chromosomes during either lytic or persistent...

  • Clonal expansions of CD8 T cells in latently HSV-1-infected human trigeminal ganglia. Held, Kathrin; Eiglmeier, Ingrid; Himmelein, Susanne; Sinicina, Inga; Brandt, Thomas; Theil, Diethilde; Dornmair, Klaus; Derfuss, Tobias // Journal of NeuroVirology;Feb2012, Vol. 18 Issue 1, p62 

    Herpes simplex virus type 1 latency in trigeminal ganglia (TG) is accompanied by a chronic immune cell infiltration. The aim of this study was to analyse the T-cell receptor �-chain repertoire in latently HSV-1 infected human TG. Using complementarity-determining region 3 spectratyping, 74...

  • Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice. Cui, F-D.; Asada, H.; Kishida, T.; Itokawa, Y.; Nakaya, T.; Ueda, Y.; Yamagishi, H.; Gojo, S.; Kita, M.; Imanishi, J.; Mazda, O. // Gene Therapy;Dec2003, Vol. 10 Issue 25, p2059 

    Naked plasmid DNA (pDNA) vaccine expressing herpes simplex virus type 1 (HSV-1) glycoprotein B (gB) was tested for protective activity against acute HSV-1 infection in mice. The pDNA was intravenously injected into Balb/c mice via their tail vein under high pressure, and the vaccination was...

  • HSV immune complex (HSV-IgG: IC) and HSV-DNA elicit the production of angiogenic factor VEGF and MMP-9. Hayashi, Kozaburo; Hooper, Laura C.; Detrick, Barbara; Hooks, John J. // Archives of Virology;Feb2009, Vol. 154 Issue 2, p219 

    Angiogenesis and inflammatory mediators are critical pathogenic factors in herpetic stromal keratitis (HSK). Since disease progresses without infectious virus, HSV-DNA and HSV-IgG complexes (HSV-IC) may contribute to HSK by triggering these factors. Production of VEGF and MMP-9 was studied in...

  • Scientists Learn Why Even Treated Genital Herpes Sores Boost the Risk of HIV Infection.  // Ethnicity & Disease;Autumn2009, Vol. 19 Issue 4, p486 

    The article focuses on the study which unveiled several reasons why patients infected with herpes simplex virus-2 (HSV-2) are at increased risk for HIV infection despite successful treatment of the genital lesions. The researchers discovered immune-cell environment in the genital skin lesions of...

  • CD34+ Cells in the Peripheral Blood Transport Herpes Simplex Virus DNA Fragments to the Skin of Patients with Erythema Multiforme (HAEM). Ono, Fumitake; Sharma, BhuvneshK.; Smith, CynthiaC.; Burnett, JosephW.; Aurelian, Laure // Journal of Investigative Dermatology;Jun2005, Vol. 124 Issue 6, p1215 

    Herpes simplex virus (HSV)-associated erythema multiforme (HAEM) is a recurrent disease characterized by the presence and expression of HSV DNA fragments in lesional skin. Our studies examined the mechanism of viral DNA transport to the skin of HAEM patients. CD34+ cells were isolated from the...

  • Innate and Adaptive Immune Responses to Herpes Simplex Virus. Chew, Tracy; Taylor, Kathryne E.; Mossman, Karen L. // Viruses (1999-4915);Dec2009, Vol. 1 Issue 3, p979 

    Immune responses against HSV-1 and HSV-2 are complex and involve a delicate interplay between innate signaling pathways and adaptive immune responses. The innate response to HSV involves the induction of type I IFN, whose role in protection against disease is well characterized in vitro and in...

  • Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors. MacTavish, Heather; Diallo, Jean-Simon; Huang, Baocheng; Stanford, Marianne; Boeuf, Fabrice Le; Silva, Naomi De; Cox, Julie; Simmons, John Graydon; Guimond, Tanya; Falls, Theresa; McCart, J. Andrea; Atkins, Harry; Breitbach, Caroline; Kirn, David; Thorne, Stephen; Bell, John C. // PLoS ONE;2010, Vol. 5 Issue 12, p1 

    Histone deacetylase inhibitors (HDI) dampen cellular innate immune response by decreasing interferon production and have been shown to increase the growth of vesicular stomatitis virus and HSV. As attenuated tumour-selective oncolytic vaccinia viruses (VV) are already undergoing clinical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics